CORT
NASDAQCorcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for CORT, including 3 insider trades, 2 press releases and news items and 2 earnings updates. The most recent was published Nov 5, 2026.
CORT rankings
Financial highlights
Full financials- Revenue, TTM
- $963.65M
- Revenue growth
- +30.0%
- Net income, TTM
- $162.29M
- Net margin
- 16.8%
- Free cash flow, TTM
- $194.62M
- Cash
- $98.72M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks83-11%
2026-05-172026-11-08
Mix3990d
- Insider27(69%)
- Other4(10%)
- SEC Filings3(8%)
- Leadership2(5%)
- Earnings2(5%)
- Analyst1(3%)
Activity · 52 weeks15681 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERMaduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,046,351 worth of shares (25,000 units at $81.85) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERPresident, Oncology Vieira Roberto Wandenkolk exercised 8,333 shares at a strike of $21.63 and sold $674,069 worth of shares (8,333 units at $80.89) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECSEC Form 10-Q filed by Corcept Therapeutics Incorporated10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- SECCorcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- PRCorcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate UpdateRevenue of $340.5 million, a 64 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $249.1 million Lifyorli® product revenue of $91.4 million Reiterated 2026 revenue guidance of $1.1 – $1.2 billion Net income of $126.8 million, compared to $19.7 million in third quarter 2025 Net income per common share (diluted) of $1.01, compared to $0.16 in third quarter 2025 Quarterly cash and investments increase of $117.7 million, to $662.3 million BELLA Part A trial results in platinum-resistant ovarian cancer: Patients who received Lifyorli (relacorilant) in addition to nab-paclitaxel and bevacizumab demonstrated clinically meaningfu
- PRCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape
- PRCorcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerLifyorli (relacorilant) in combination with nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the more pronounced results being in patients who had no prior treatment with bevacizumab. Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company’s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclit
- PR2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesJoint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026, which recommends that clinicians scr
- INSIDERDirector Wilson James N sold $1,148,083 worth of shares (10,000 units at $114.81) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERPresident, Oncology Vieira Roberto Wandenkolk sold $967,448 worth of shares (8,333 units at $116.10) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas sold $1,160,731 worth of shares (10,000 units at $116.07) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean sold $2,906,601 worth of shares (25,000 units at $116.26) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Corcept Therapeutics Incorporated4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 3 filed by Corcept Therapeutics Incorporated3 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles gifted 17,100 shares and received a gift of 10,000 shares, decreasing direct ownership by 55% to 14,056 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECCorcept Therapeutics Incorporated filed SEC Form 8-K: Regulation FD Disclosure8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- PRCorcept Announces Planned Leadership TransitionSean Maduck to Retire; Justin Gunn Appointed President, Endocrinology Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October 1. Mr. Gunn will join the company’s Executive Team, and will report to Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. To enable a smooth transition, Mr. M
- INSIDERPresident, Oncology Vieira Roberto Wandenkolk sold $29,843 worth of shares (296 units at $100.82) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 3,946 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles exercised 17,493 shares at a strike of $8.27, increasing direct ownership by 128% to 31,156 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- PRCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients
- INSIDEROfficer Lyon Joseph Douglas exercised 10,000 shares at a strike of $12.99 and sold $1,134,947 worth of shares (10,000 units at $113.49) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Wilson James N sold $1,106,940 worth of shares (10,000 units at $110.69) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- PRBloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector Sept 21, 2026 S&P 100AdditionDell Techno
- INSIDERChief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
CORT FAQ
11 questionsWhat does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in...What is the latest news on CORT?
In the last 30 days Quantisnow tracked 9 wire items for CORT: 3 insider trades, 2 press releases and news items, 2 earnings updates and 2 SEC filings. The most recent was published on November 5, 2026.What is CORT revenue?
Corcept Therapeutics Incorporated (CORT) reported $963.65M of revenue for the twelve months ended Sep 30, 2026. That is up 30.0% from the year before. Revenue for fiscal 2025 was $761.41M.Is CORT profitable?
Yes. Corcept Therapeutics Incorporated earned $162.29M in net income for the twelve months ended Sep 30, 2026, a net margin of 16.8%.How much cash and debt does CORT have?
Corcept Therapeutics Incorporated reported $98.72M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CORT stock trade?
Corcept Therapeutics Incorporated (CORT) is listed on NASDAQ.What sector and industry is CORT in?
Corcept Therapeutics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corcept Therapeutics Incorporated go public?
Corcept Therapeutics Incorporated (CORT) completed its IPO in 2004.What are analysts saying about CORT?
Across the last 8 analyst actions on Corcept Therapeutics Incorporated, there were 3 upgrades and 2 downgrades. The most recent action was from Truist: Buy with a $164.00 price target on 2026-08-18.What companies are similar to CORT?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare CORT side-by-side with any of them on Quantisnow.How can I track CORT on Quantisnow?
Quantisnow aggregates Corcept Therapeutics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CORT to receive live email and push alerts on every new disclosure.